Oregon is currently home to 1243 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US301, Portland, Oregon
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Florence, Oregon
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Asante Rogue Regional Medical Center, Medford, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Oregon Medical Research Center, Pc, Portland, Oregon
Conditions: NonSegmental Vitiligo
Register for Updates
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Portland, Oregon
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Oncology Associates of Oregon, P.C., Eugene, Oregon
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304
Recruiting
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
04/25/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT05620823
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US301, Portland, Oregon
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096
Recruiting
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Portland, Oregon
Conditions: Generalized Myasthenia Gravis
Register for Updates
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367
Recruiting
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697
Recruiting
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Advanced Solid Tumors
Register for Updates